CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Condition(s):Relapsed/Refractory Acute Myeloid Leukemia(AML)Last Updated:September 13, 2021Terminated
Hide Studies Not Open or Pending
Condition(s):Relapsed/Refractory Acute Myeloid Leukemia(AML)Last Updated:September 13, 2021Terminated
Condition(s):Relapsed Acute Myeloid LeukemiaLast Updated:December 28, 2022Completed
Condition(s):AMLLast Updated:July 5, 2023Not yet recruiting
Condition(s):Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid LeukemiaLast Updated:July 21, 2017Completed
Condition(s):Acute Myelocytic LeukemiaLast Updated:January 11, 2019Unknown status
Condition(s):Acute Myeloid Leukemia; Invasive AspergillosisLast Updated:September 14, 2016Completed
Condition(s):Antineoplastic Adverse Reaction; Thrombocytopenia; Acute Myelocytic LeukemiaLast Updated:April 20, 2016Unknown status
Condition(s):Acute Myelocytic LeukemiaLast Updated:December 22, 2022Completed
Condition(s):Acute Myeloid LeukemiaLast Updated:January 3, 2020Unknown status
Condition(s):Acute Myeloid Leukemia, in RelapseLast Updated:July 21, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.